Startup profile for Alpine Bio: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.

Startup profile · funding coverage

Alpine Bio funding, valuation and investors

Biomanufacturing platform producing animal-free dairy proteins via engineered plants.

Keep track of Alpine Bio

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Series B

$75M · 2021

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

$75M

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

series b

Investors in latest funding

Other: Andreessen Horowitz

Sources: latest funding: Series B (2021): $75M with a16z, Pear VC, AgFunder participation (AgFunderNews) Last verified: 2026-07-25

Overview

Alpine Bio (formerly Nobell Foods) uses molecular farming — engineering plants to produce animal-free dairy proteins like casein without cows.

Why Alpine Bio is interesting

Alpine Bio (ex-Nobell) scales casein without cows — a16z bio bet alongside Pear and ag-focused syndicate.

Product & use cases

Alpine Bio (formerly Nobell Foods) uses molecular farming — engineering plants to produce animal-free dairy proteins like casein without cows.

  • Primary product use case per company site
  • Enterprise or consumer deployment

Key facts

  • Series B (2021): $75M with a16z, Pear VC, AgFunder participation (AgFunderNews)
  • Formerly Nobell Foods — plant-based casein via molecular farming

Funding history (newest first)

Series B

2021 $75M

Source: Series B (2021): $75M with a16z, Pear VC, AgFunder participation (AgFunderNews)

Investors in our directory

Funds linked from Alpine Bio's profile — open a fund page for stage focus and related deal articles.

Competitive landscape

Edge: Alpine Bio (ex-Nobell) scales casein without cows — a16z bio bet alongside Pear and ag-focused syndicate.

Alpine Bio competes in biotech-life-sciences, climate-tech. Incumbents have distribution; startup edge depends on product depth and buyer references. See competitors for specific tradeoffs — no invented market share claims.

  • Veeva incumbent

    Life sciences cloud incumbent.

  • Dotmatics adjacent

    R&D informatics.

  • Tesla Energy adjacent

    Distributed energy incumbent.

  • Sunrun adjacent

    Residential solar/storage.

Notable stories

  • Formerly Nobell Foods — plant-based casein via molecular farming

Industries

Biotech & Life Sciences Climate Tech

Related funding articles

Venture Capital Tracker pieces that cover Alpine Bio's financing or category context.

FAQs about Alpine Bio

Practical answers founders, operators, and investors typically search for.

Alpine Bio (formerly Nobell Foods) uses molecular farming — engineering plants to produce animal-free dairy proteins like casein without cows.
Directory-linked investors include /fund/andreessen-horowitz, /fund/pear-vc.
series-b stage, private status. Series B (2021): $75M with a16z, Pear VC, AgFunder participation (AgFunderNews)
Private as of July 2026 (status: private).
See fundraisingRounds for verified dates and disclosed amounts.
See competitors section — named alternatives with honest positioning notes.
Not publicly disclosed unless noted in highlights.
HQ not publicly listed on profile.

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.